BLA 125118 · Bristol Myers Squibb
Orencia
Abatacept · Iv (Infusion) · Selective T Cell Costimulation Modulator
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: May 29, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Dec 23, 2005
Approved uses
11
Original approval plus efficacy supplements
Registered trials
256
62 Phase 3, 34 recruiting
FAERS reports
139,985
83,534 serious, 9,486 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 13, 2025.
ORENCIA is a selective T cell costimulation modulator indicated for: • the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). (1.1) • the treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA). (1.2) • the treatment of patients 2 years of age and older with active psoriatic arthritis (PsA). (1.3) • the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor. (1.4) Limitations of Use: Concomitant use of ORENCIA with other immunosuppressives [e.g., biologic disease-modifying antirheumatic drugs (bDMARDS), Janus kinase (JAK) inhibitors] is not recommended. ( 1.5 , 5.1) 1.1 Adult Rheumatoid Arthritis ORENCIA ® is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). 1.2 Polyarticular Juvenile Idiopathic Arthritis ORENCIA is indicated for the treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA). 1.3 Psoriatic Arthritis ORENCIA is indicated for the treatment of patients 2 years of age and older with active psoriatic arthritis (PsA). 1.4 Prophylaxis for Acute Graft versus Host Disease ORENCIA is indicated for the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor. 1.5...
Mechanism: Abatacept, a selective costimulation modulator, inhibits T-cell (T lymphocyte) activation by binding to CD80 and CD86, thereby blocking interaction with CD28. This interaction provides a costimulatory signal necessary for full activation of T lymphocytes. Activated T lymphocytes are implicated in the pathogenesis of RA, pJIA and PsA and are found in the synovium of patients with RA, pJIA and PsA. In vitro , abatacept decreases T-cell proliferation and inhibits the production of the cytokines TNF alpha (TNFα), interferon-γ, and interleukin-2. In a rat collagen-induced arthritis model,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 30, 2023 Supplement 250 · Efficacy OrphanLabelLetter
- Dec 15, 2021 Supplement 240 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
- Jun 30, 2017 Supplement 209 · Efficacy LabelLetter
- Mar 30, 2017 Supplement 211 · Efficacy · priority review LabelLetterPediatric Medical Review
- Jun 7, 2016 Supplement 200 · Efficacy
- Dec 20, 2013 Supplement 171 · Efficacy LabelLetter
- Jul 29, 2011 Supplement 122 · Efficacy ReviewLetter
- Aug 25, 2009 Supplement 86 · Efficacy LabelLetter
- Apr 7, 2008 Supplement 45 · Efficacy Pediatric Statistical ReviewPediatric Written RequestLetter
- Mar 13, 2007 Supplement 16 · Efficacy Label
- Dec 23, 2005 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelPediatric Clinical Pharmacology ReviewPediatric Clinical Pharmacology Addendum
1 products under this application
- ORENCIA · ABATACEPT 250MG · INJECTABLE, IV (INFUSION) · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Abatacept" as an intervention, any sponsor and status, largest first.
- Methotrexate-Inadequate Response StudyPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00559585 · 2,492 participants · Start Jan 2008 · Primary completion Nov 2009
Drug: Subcutaneous (SC) Abatacept; Intravenous (IV) Abatacept · For: Rheumatoid Arthritis (RA)
Sites: Birmingham, Alabama; Mobile, Alabama; Scottsdale, Arizona · 203 sites in all
- Immune Modulators for Treating COVID-19Pivotal-lookingCompleted
Daniel BenjaminAcademic, hospital or other
NCT04593940 · 1,971 participants · Start Oct 15, 2020 · Primary completion Jan 30, 2022
Drug: Infliximab; Abatacept and 2 more · For: Covid19
Sites: Phoenix, Arizona; Little Rock, Arkansas; La Jolla, California · 91 sites in all
- A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid ArthritisPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00048932 · 1,795 participants · Start Dec 2002 · Primary completion Oct 2009
Drug: Double-blind Abatacept; Double-blind Placebo and 1 more · For: Rheumatoid Arthritis
Sites: Decatur, Alabama; Paradise, Arizona; Phoenix, Arizona · 44 sites in all
- Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF TherapyPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00124982 · 1,286 participants · Start Apr 2005 · Primary completion Aug 2009
Drug: Abatacept; Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) and 1 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Paradise Valley, Arizona · 148 sites in all
- A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to MethotrexatePivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00048568 · 1,250 participants · Start Dec 2002 · Primary completion Oct 2009
Drug: Abatacept; Methotrexate and 1 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 48 sites in all
- Remission and Joint Damage Progression in Early Rheumatoid ArthritisPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00122382 · 1,052 participants · Start Jul 2005 · Primary completion Feb 2008
Drug: Abatacept; placebo and 1 more · For: Rheumatoid Arthritis
Sites: Huntsville, Alabama; Huntington Beach, California; Colorado Springs, Colorado · 89 sites in all
- Effects of Abatacept in Patients With Early Rheumatoid ArthritisPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02504268 · 994 participants · Start Sep 3, 2015 · Primary completion Jan 16, 2017
Drug: Abatacept; Methotrexate · For: Rheumatoid Arthritis
Sites: Huntsville, Alabama; Glendale, Arizona; Mesa, Arizona · 201 sites in all
- RA-PRO PRAGMATIC TRIALPivotal-lookingRecruiting
University of Alabama at BirminghamAcademic, hospital or other
NCT04692493 · 924 participants (planned) · Start Sep 22, 2021 · Primary completion May 31, 2029
Drug: targeted synthetic DMARD class; non-TNFi-biologic class · For: Rheumatoid Arthritis
Sites: Auburn, Alabama; Birmingham, Alabama; Peoria, Arizona · 49 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective39,195
- rheumatoid arthritis24,856
- pain22,227
- arthralgia21,734
- joint swelling20,948
- fatigue14,613
- contraindicated product administered14,115
- rash13,429
- drug intolerance13,300
- off label use12,277
- arthropathy11,847
- alopecia10,772
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 15 |
| 2005 | 12 |
| 2006 | 346 |
| 2007 | 470 |
| 2008 | 778 |
| 2009 | 313 |
| 2010 | 867 |
| 2011 | 562 |
| 2012 | 1,591 |
| 2013 | 2,580 |
| 2014 | 2,967 |
| 2015 | 4,561 |
| 2016 | 6,760 |
| 2017 | 9,924 |
| 2018 | 12,798 |
| 2019 | 14,017 |
| 2020 | 18,058 |
| 2021 | 13,719 |
| 2022 | 13,229 |
| 2023 | 9,505 |
| 2024 | 10,625 |
| 2025 | 9,654 |
| 2026 | 6,634 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Orencia (Abatacept)
2024 spending
$184M
Beneficiaries
4,112
30,087 claims
Per beneficiary
$44,728
$1,406.77 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $172,167,789 |
| 2021 | $168,467,143 |
| 2022 | $170,833,810 |
| 2023 | $178,400,675 |
| 2024 | $183,919,526 |
Part D: Orencia (Abatacept/Maltose)
2024 spending
$64.6M
Beneficiaries
2,034
13,822 claims
Per beneficiary
$31,743
$1,431.35 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $29,667,287 |
| 2021 | $34,952,685 |
| 2022 | $45,960,310 |
| 2023 | $53,626,257 |
| 2024 | $64,565,143 |
Part B: Orencia* (Abatacept*) · HCPCS J0129
2024 spending
$930M
Beneficiaries
33,154
291,579 claims
Per beneficiary
$28,062
2024 ASP limit $43.29 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,023,005,572 |
| 2021 | $988,943,742 |
| 2022 | $903,326,017 |
| 2023 | $902,527,110 |
| 2024 | $930,380,811 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Immune Checkpoint Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis.
Nielsen DL, Juhl CB, Nielsen OH, et al. · JAMA Oncol 2024 · Systematic Review, Meta-Analysis
- Corticosteroid-resistant immune-related adverse events: a systematic review.
Daetwyler E, Wallrabenstein T, König D, et al. · J Immunother Cancer 2024 · Research Support, Non-U.S. Gov't, Systematic Review
- Treatment of relapsing polychondritis: a systematic review.
Petitdemange A, Sztejkowski C, Damian L, et al. · Clin Exp Rheumatol 2022 · Systematic Review
- Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.
Rubbert-Roth A, Enejosa J, Pangan AL, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Comparative Study
- Treatment Strategies for GLILD in Common Variable Immunodeficiency: A Systematic Review.
Lamers OAC, Smits BM, Leavis HL, et al. · Front Immunol 2021 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis.
Narváez J, Aguilar-Coll M, Roig-Kim M, et al. · Autoimmun Rev 2024 · Systematic Review, Meta-Analysis
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.